Approved for use through 03/31/2007. OMB 0681-080 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Linder the Panenwork Reduction Act of 1995

Onder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information to	
TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) CLFR:178USD1
In re Application of: Bob G. Sanders, et al.	
Application No.: 10/695,275	
Filed: October 28, 2003	
For: TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF	
The owner*, <u>Research Development Eoundation</u> of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would active the experision date of the full statutory term prior patent No. <u>6.645.938</u> . as the term of said prior patent is defined in 35 U.S.C. 134 and 173, and as the term of said prior patent is defined in 35 U.S.C. 134 and 173, and as the term of said prior patent is presently shortened by any terminal disclaiment. The owner hereby agrees that any patent as granted on the instant application and is bending upon the granter, the owner hereby agrees that any patent granted on the instant application and is befinding upon the granter, its successor or assigns.	
In making the above discalatiner, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in SU SL.C. 154 and 73 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canciated by a recursamination certificate; to reliasued; for nament terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 	
I hereby declare that all statements made herein of my own knowledge are fuve and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willfull false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 16 of the United States Code and that such willful false statements may legoradrize the validity of the application or any patient issued thereon.	
The undersigned is an attorney or agent of record. Reg. No. 58,112	
*// ./ .	
	April 24, 2007
Sphature	Date
Mark H. Voges	
Typed or printed name	
	512-536-3116 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP \$ 324.	

This objection of information is required by 7 CEF 1.32. The information is required to obtain or rotatin a benefit by the gobbic which is to file (and by the USPTO to possible on impleation). Confidentially is a payment by 5 VB 1.55. CT.22 and 37 CEF 1.1 Intel of 1.18 in December to be settlement to boost Personal Complete including gaithering, preparing, and submitting the completed application from to the USPTO. Then will very decrease and submitting the complete the STR in and Confidential Complete the STR in and Confidential Co